PLRX Company Profile and Key Details

Q: Who are the executives of PLRX?

Mr. Mike OuimetteGen. Counsel & Corporation Sec.Mr. Hal Chapman M.D.Scientific Founder & Member of Scientific Advisory BoardDr. Rik DerynckScientific Founder & Member of Scientific Advisory BoardMr. Johannes P. HullChief Bus. OfficerMr. Bill DeGrado Ph.D.Scientific Founder & Member of Scientific Advisory BoardDr. Keith Lamont Cummings M.B.A., M.D.Chief Financial OfficerDr. Éric Lefebvre M.D.Chief Medical OfficerMr. Craig D. MuirInterim Chief Technology OfficerMr. Dean Sheppard M.D.Scientific Founder & Member of Scientific Advisory BoardMr. Mike Ouimette J.D.Gen. Counsel & Corporation Sec.Dr. Bernard Coulie M.B.A., M.D., MBA, Ph.D.Pres, Chief Executive Officer & Director

NASDAQ : PLRX

Pliant Therapeutics

$1.19

-0.01-0.83%

At Close 4:00 PM

58.8

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Pliant Therapeutics, Inc. (PLRX) stock declined over -0.83%, trading at $1.19 on NASDAQ, down from the previous close of $1.20. The stock opened at $1.20, fluctuating between $1.19 and $1.23 in the recent session.

Stock Snapshot

1.2

Prev. Close

73.68M

Market Cap

1.19

Day Low

-0.49

P/E Ratio

-2.43

EPS (TTM)

-1.96

Cash Flow per Share

1.2

Open

61.91M

Number of Shares

1.23

Day High

83.87%

Free Float in %

7.91

Book Value

305.59K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 04, 2026	1.20	1.23	1.19	1.19	305.8K
Apr 30, 2026	1.22	1.23	1.20	1.22	363.46K
Apr 29, 2026	1.20	1.22	1.18	1.21	290.06K
Apr 28, 2026	1.20	1.23	1.20	1.21	243.67K
Apr 27, 2026	1.24	1.26	1.21	1.21	393.79K
Apr 23, 2026	1.28	1.31	1.25	1.26	432.23K
Apr 22, 2026	1.30	1.33	1.26	1.29	1.16M
Apr 21, 2026	1.28	1.31	1.26	1.29	750.77K
Apr 20, 2026	1.35	1.35	1.16	1.29	2.32M
Apr 17, 2026	1.30	1.38	1.30	1.33	424.47K
Apr 16, 2026	1.31	1.33	1.29	1.30	399.61K
Apr 14, 2026	1.31	1.35	1.29	1.30	186.52K
Apr 13, 2026	1.28	1.33	1.26	1.30	167.62K
Apr 10, 2026	1.35	1.37	1.28	1.28	546.17K
Apr 09, 2026	1.36	1.37	1.32	1.35	213.22K
Apr 08, 2026	1.34	1.36	1.31	1.36	298.89K
Apr 07, 2026	1.30	1.32	1.27	1.31	422.04K
Apr 06, 2026	1.34	1.38	1.31	1.31	515.92K
Apr 02, 2026	1.30	1.38	1.28	1.35	521.6K
Apr 01, 2026	1.27	1.33	1.27	1.32	523.06K

Contact Details

South San Francisco, CA 94080

United States

https://pliantrx.com 650 481 6770

About Company

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of av�6 and av�1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of av�1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Stock Peers

ARGX

27.59+3.52%

argenx SE$811.09 REGN

7.79+1.11%

Regeneron Pharmaceuticals, Inc.$709.21 UTHR

10.82+1.90%

United Therapeutics Corporation$581.22 MDGL

4.94002+0.96%

Madrigal Pharmaceuticals, Inc.$518.66 VRTX

5.93+1.40%

Vertex Pharmaceuticals Incorporated$429.85 PRAX

13.41+4.14%

Praxis Precision Medicines, Inc.$337.61 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

1.815+0.61%

Alnylam Pharmaceuticals, Inc.$297.93 KRYS

20.91+7.86%

Krystal Biotech, Inc.$286.95 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Pliant Therapeutics, Inc. (NASDAQ:PLRX) closed at $1.19 USD, losing -$0.01 (-0.83%) from the previous close of $1.20. The stock is currently mid-range between its 52-week high and low $1.09 and $1.95. With a market capitalization of about $73.68 million, Pliant Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.25). Key stats such as the average daily volume over the past year has been around 577.90 thousand shares, volume is running light vs its 52-week average. Headquartered in South San Francisco, CA, Pliant Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Bernard Coulie, the company employs approximately 171 people and listed since June 03, 2020. Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States.

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 7.66%, SMA50 4.18%, SMA200 -10.5%). The stock’s 14-day RSI is 57.19 (neutral), while the ATR of 0.07 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -62.72% below its high and over 18.35% above its low. Average 10-day trading volume of 319.36 thousand shares is below the 3-month average of 605.08 thousand, indicating normal recent market interest.

Valuation Metrics

Pliant Therapeutics, Inc. trades at a P/E ratio of -0.5, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.41 suggesting the stock is closer to book value. The P/FCF stands at -0.58, also below market averages.

Dividend & Fair Value

Pliant Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.27. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Pliant Therapeutics, Inc. generated EPS of -$2.87 over the past year. Five-year average earnings growth is -78.3%. Wall Street analysts project EPS growth of 30.98% annually over the next five years. The latest quarter delivered EPS of -$0.35. The next quarter is forecast at -$0.40. Next year's EPS is expected at -$20.22. Analyst sentiment is neutral. Analyst rating data shows there are 2 Strong Buy ratings, 0 Buy ratings, 2 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $4.00 to $2.00. The high target offers 236.13% upside. The low target suggests 68.07% downside. The mean target is $3.25. This offers 173.11% upside. Pliant Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended March 11, 2026, missed forecasts by -16.67%. The prior quarter beat by -18.87%. Over the last six quarters, Apple has recorded several small beats. These include -2.06% in November 07, 2024.

Shareholding & Insider Activity

Pliant Therapeutics, Inc. has 61.39 million shares outstanding. The public float is 55.57 million shares, elevated short interest at 5.47% of float. This equals 3.28 million shares. The short ratio is 2.6 days. Institutional investors hold 88.39% of the float. Insiders own 3.04%. Coulie Bernard holds 505.60 thousand shares, Cummings Keith Lamont has 297.21 thousand shares and Hull Hans has 211.56 thousand shares. Over the past six months, insider transactions show net selling. They sold 127.83 thousand shares across 4 transactions.

Financial & Profitability Overview

Over the trailing twelve months, Pliant Therapeutics generated $1.58M in revenue, or $0.03 per share. Gross margin was -16.52%, operating margin -11654.75%, and net profit margin -10211.14%. Returns are negative, with ROA at -31.50% and ROE at -34.07%.
On valuation metrics, Pliant Therapeutics trades at a P/E of -0.50, P/S of 0.00 and P/B of 0.41. The current ratio is 12.00 and quick ratio is 12.00. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -215.76 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 0.16, supported by a cash flow-to-debt ratio of -4.41.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Pliant Therapeutics posted revenue of $1.58M, down slightly from $9.69M in the prior quarter. Gross profit was - $261.00K (margin -16.52%). Operating income was - $184.15M (margin -11654.7%). Net income was- $161.34M (EPS - $2.75).
The company ended the quarter with $494.25M in cash and short-term investments, a total debt of $11.37M, and net debt of - $51.86M. Total assets were $512.15M, with equity of $473.58M. Financials further reflected weakness, with operating cash flow of - $116.36M, free cash flow of - $117.28M, and capital expenditures of - $921.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Pliant Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.36%, with price expected at $1.15 by May 18, 2026, within a range of $1.09 to $1.20 3-Month Outlook: Projected rise of 2838.66%, reaching $34.97 by July 31, 2026, with a range of $33.25 to $37.74. 1-Year Outlook: Projected loss of -12.61%, with price at $1.04 by May 04, 2027, within a range of $0.00 to $0.00.

Key Takeaways

Pliant Therapeutics, Inc. (NASDAQ:PLRX) shares are flat 4.92% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Pliant Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.5. Analyst sentiment is mixed, with the majority of ratings in Hold territory and a mean price target of $34.97, suggesting 2838.66% upside. Our AI forecast model points to short-term weakness (-3.36% over two weeks), a medium-term rise (2838.66% over three months), and a longer-term loss (-12.61% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Pliant Therapeutics, Inc. (PLRX) stock price?

Pliant Therapeutics, Inc. (NASDAQ: PLRX) stock price is $1.19 in the last trading session. During the trading session, PLRX stock reached the peak price of $1.23 while $1.19 was the lowest point it dropped to. The percentage change in PLRX stock occurred in the recent session was -0.83% while the dollar amount for the price change in PLRX stock was - $0.01.

PLRX's industry and sector of operation?

The NASDAQ listed PLRX is part of Biotechnology industry that operates in the broader Healthcare sector. Pliant Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of PLRX?

Mr. Mike Ouimette
Gen. Counsel & Corporation Sec.
Mr. Hal Chapman M.D.
Scientific Founder & Member of Scientific Advisory Board
Dr. Rik Derynck
Scientific Founder & Member of Scientific Advisory Board
Mr. Johannes P. Hull
Chief Bus. Officer
Mr. Bill DeGrado Ph.D.
Scientific Founder & Member of Scientific Advisory Board
Dr. Keith Lamont Cummings M.B.A., M.D.
Chief Financial Officer
Dr. Éric Lefebvre M.D.
Chief Medical Officer
Mr. Craig D. Muir
Interim Chief Technology Officer
Mr. Dean Sheppard M.D.
Scientific Founder & Member of Scientific Advisory Board
Mr. Mike Ouimette J.D.
Gen. Counsel & Corporation Sec.
Dr. Bernard Coulie M.B.A., M.D., MBA, Ph.D.
Pres, Chief Executive Officer & Director

How PLRX did perform over past 52-week?

PLRX's closing price is 9.17% higher than its 52-week low of $1.09 where as its distance from 52-week high of $1.95 is -38.97%.

How many employees does PLRX have?

Number of PLRX employees currently stands at 171.

Link for PLRX official website?

Official Website of PLRX is: https://pliantrx.com

How do I contact PLRX?

PLRX could be contacted at phone 650 481 6770 and can also be accessed through its website. PLRX operates from 260 Littlefield Avenue, South San Francisco, CA 94080, United States.

How many shares of PLRX are traded daily?

PLRX stock volume for the day was 305.59K shares. The average number of PLRX shares traded daily for last 3 months was 577.9K.

What is the market cap of PLRX currently?

The market value of PLRX currently stands at $73.68M with its latest stock price at $1.19 and 61.91M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	171
Beta	1.25
Sales or Revenue	$1.58M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

PLRX Company Profile and Key Details

Pliant Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Financial & Profitability Overview

Quarterly Financial Highlights

Valuation Metrics

Shareholding & Insider Activity

Key Takeaways

Price Forecast & Outlook